Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yun Jung | - |
dc.contributor.author | Ah, Young-Mi | - |
dc.contributor.author | Kong, Jisun | - |
dc.contributor.author | Choi, Kyung Hee | - |
dc.contributor.author | Kim, Baegeum | - |
dc.contributor.author | Han, Nayoung | - |
dc.contributor.author | Yu, Yun Mi | - |
dc.contributor.author | Oh, Jung Mi | - |
dc.contributor.author | Shin, Wan Gyoon | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Lee, Ju-Yeun | - |
dc.date.accessioned | 2022-04-30T10:40:08Z | - |
dc.date.available | 2022-04-30T10:40:08Z | - |
dc.date.created | 2022-04-30 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 1755-5914 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84184 | - |
dc.description.abstract | AimPotential heterogeneity within the same class of drug in terms of persistence may lead to different clinical implications. Given that the increased risks of mortality and cardiovascular events are due, in part, to the lack of persistent use of antihypertensive medications, the objective of this study was to evaluate 1-year persistence of new-generation beta blockers compared to atenolol in antihypertensive treatment-naive patients. MethodsA total of 9978 patients aged 18years or older with hypertension newly diagnosed in 2012, without hypertension-related complication and initiated treatment with beta blocker monotherapy during 2012 were included in the analysis. Rate and duration of treatment and drug persistence were compared between atenolol and new-generation beta blockers. Hazards of discontinuation in nonatenolol compared to atenolol were evaluated using a multivariate Cox proportional model. ResultsThe rate of treatment persistence was higher in the nonatenolol group (57.35% vs 53.40%, P<.0001), and the time to treatment discontinuation was earlier in the atenolol group with a minimal difference in the average (243.2 vs 254days, P<.0001). New-generation beta blockers demonstrated a lower risk of treatment discontinuation (HR: 0.91, 95% CI: 0.86-0.96) compared to atenolol; a notable improvement was observed with carvedilol and nebivolol (HR: 0.74, 95% CI: 0.69-0.80 and HR: 0.79, 95% CI: 0.70-0.89, respectively), whereas betaxolol showed a substantially greater hazard for discontinuation compared to atenolol. ConclusionsThis study demonstrated a meaningful improvement in treatment persistence with new-generation beta blockers compared to atenolol, with betaxolol as exception. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-HINDAWI | - |
dc.relation.isPartOf | CARDIOVASCULAR THERAPEUTICS | - |
dc.title | Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000379925500011 | - |
dc.identifier.doi | 10.1111/1755-5922.12197 | - |
dc.identifier.bibliographicCitation | CARDIOVASCULAR THERAPEUTICS, v.34, no.4, pp.268 - 275 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84978975638 | - |
dc.citation.endPage | 275 | - |
dc.citation.startPage | 268 | - |
dc.citation.title | CARDIOVASCULAR THERAPEUTICS | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Hee | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | adherence | - |
dc.subject.keywordAuthor | atenolol | - |
dc.subject.keywordAuthor | betaxolol | - |
dc.subject.keywordAuthor | new-generation beta blocker | - |
dc.subject.keywordAuthor | persistence | - |
dc.subject.keywordPlus | NEWLY TREATED PATIENTS | - |
dc.subject.keywordPlus | MEDICATION ADHERENCE | - |
dc.subject.keywordPlus | ANTIHYPERTENSIVE THERAPY | - |
dc.subject.keywordPlus | HYPERTENSIVE PATIENTS | - |
dc.subject.keywordPlus | DRUG CLASS | - |
dc.subject.keywordPlus | DISCONTINUATION | - |
dc.subject.keywordPlus | NEBIVOLOL | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.